Chitosan is one of the most widely used materials drawn from the natural world. Most of it comes from the shells of shrimp and crab, so people with shellfish allergy reasonably ask whether a chitosan-containing product could trigger a reaction. This article explains what actually causes shellfish allergy and what the industrial purification of chitosan does to the responsible proteins. It then sets out what the small number of published skin and oral challenge studies show and where the evidence stops. The short version is that shellfish allergy is caused by proteins, not by the shell's sugar framework. Well-purified chitosan contains little or none of those proteins, and the human studies so far are reassuring. Those studies are also small, and manufacturing quality varies.

What actually causes shellfish allergy

Shellfish allergy is an immune reaction mediated by immunoglobulin E (IgE) against specific proteins in the animal's muscle and other tissues. The dominant one is tropomyosin, a muscle protein first characterised in brown shrimp as the allergen Pen a 1. It was described in work associated with Tulane University and Samuel Lehrer's group in the 1990s. Tropomyosin is a "pan-allergen." Its structure is so similar across crustaceans and molluscs that people sensitised to shrimp often react to crab, lobster and sometimes clams or squid. It is also strikingly heat-stable, which is why cooked shellfish remains allergenic.

Tropomyosin is not the only culprit. Researchers have identified several other shellfish allergens:

Individual patients may be sensitised to different combinations of these proteins. Tropomyosin also explains a cross-reactivity that surprises many people. House dust mites and cockroaches carry closely related tropomyosins (Der p 10 and Bla g 7). Some people with shellfish allergy were first sensitised to mites, and vice versa.

The crucial point for this discussion is that every known shellfish allergen is a protein. None of them is chitin, the long sugar-based polymer that gives the shell its strength.

From shell to chitosan: what purification does to protein

Chitin is among the most abundant natural polymers on earth. It forms the shells of crustaceans, the exoskeletons of insects and the cell walls of fungi. There is something fitting in how a material built for protection in one creature can be refined into a useful substance for another. The refining is rigorous, though, and that is what matters for allergy. Commercial production from shellfish waste typically involves three chemical stages:

Hot, strongly alkaline conditions break proteins down into fragments and amino acids, and the material is repeatedly washed. In principle, little intact tropomyosin should survive. In practice, the outcome depends on how well each step is run. Manufacturers grade chitosan by degree of deacetylation, molecular weight, ash and residual protein. Pharmaceutical- and biomedical-grade material is held to tighter specifications than technical or agricultural grades.

Low residual protein is not the same as zero allergen. Even a small amount of an intact or partly intact protein fragment can matter to a highly sensitised person. Independent, published testing of commercial chitosan specifically for tropomyosin is limited. This is one of the genuine gaps in the evidence.

There is also a fully separate supply route. Chitosan can be made from fungal sources, most commonly the mould Aspergillus niger or mushroom material, with no shellfish involved. Fungal chitosan has been evaluated by European food-safety regulators for uses such as wine processing. Some manufacturers offer it precisely because it removes the shellfish question entirely.

What the oral challenge studies show

No well-known controlled oral food challenge has tested chitosan itself in shellfish-allergic people. The closest human evidence comes from glucosamine, a supplement typically made by breaking down shellfish chitin even further. These studies tell us whether shellfish-derived carbohydrate products carry enough allergen to provoke reactions when swallowed.

The first was a double-blind, placebo-controlled study from Saint Louis University. It was published as a report in the Journal of Allergy and Clinical Immunology in 2004 by Gray, Hutcheson and Slavin. Fifteen adults with shellfish allergy, confirmed by history plus skin testing and specific IgE, took a standard dose of glucosamine-chondroitin. None had an immediate reaction, and none reported delayed reactions in follow-up.

The second was a double-blind, placebo-controlled food challenge reported in Clinical and Experimental Allergy in 2006 by Villacis and colleagues, with Lehrer's group at Tulane. It used glucosamine confirmed to be shrimp-derived. Six participants with documented shrimp allergy took glucosamine at typical supplement doses, and none reacted. The investigators also analysed the product and did not detect shrimp allergen in it.

These studies are rigorous in design. Blinding and placebo control are the gold standard for food challenges. Their size is very small, however, and fifteen or six people cannot rule out a rare reaction. Glucosamine is also more extensively processed than chitosan, so its results support chitosan only by reasonable inference, not direct proof. Glucosamine is a dietary supplement and is not an approved drug for any condition.

What the skin studies show

Skin evidence is particularly relevant to topical products. Here the main published data come from military medicine, where chitosan-based haemostatic dressings came into wide field use for controlling bleeding. A study from Brooke Army Medical Center was published in Military Medicine in 2011 by Waibel and colleagues. It examined the safety of a chitosan dressing in adults with documented shellfish allergy.

Participants received skin prick testing with extracts of the dressing material, alongside shellfish and control tests. The dressing was then applied to their skin. The researchers reported no positive skin tests to the chitosan material and no reactions to direct application, even though participants reacted to shellfish itself.

This was again a small study, and it tested one manufacturer's highly purified medical-grade product. Results cannot automatically be extended to every chitosan on the market. Still, it is direct human evidence that well-made chitosan placed on the skin of shellfish-allergic people did not provoke the expected IgE response.

Beyond these controlled studies, the published literature contains very few reports of allergic reactions to chitosan. Where reactions to chitosan-containing products have been described, it is often unclear whether chitosan, a residual protein or another ingredient was responsible.

Where the evidence runs out

An honest account has to name the limits.

Stewardship for allergic patients and families

Each person with a food allergy has a body worth protecting with care. For most shellfish-allergic people, the evidence suggests that well-purified chitosan is unlikely to be a problem. "Unlikely" is a judgement best made with your own physician, who knows your history and test results. The questions below are worth discussing with your doctor or with an allergist.

Topical products such as GermProof, which combine chelated silver with chitosan, are skin products, not approved drugs. Their ingredient sourcing is a reasonable thing for an allergic person to ask about before use. Careful preparedness belongs alongside any such decision: keep prescribed epinephrine on hand and make sure family members know your allergy. Informed consent means understanding both what the studies show and how much they leave unanswered.

Key takeaway: Shellfish allergy is caused by proteins such as tropomyosin, which careful chitosan purification largely removes, and small but well-designed skin and oral studies have found no reactions in shellfish-allergic volunteers, though their limited size and variable product quality mean decisions are best made with your own physician.